...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and laboratory haematology >Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.
【24h】

Myeloablative allogeneic stem cell transplantation for advanced stage multiple myeloma: very long-term follow up of a single center experience.

机译：晚期异型多发性骨髓瘤的清髓性同种异体干细胞移植：单个中心经验的长期随访。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Summary We aimed to review the long-term outcome of myeloablative allogeneic stem cell transplantation (SCT) performed for multiple myeloma (MM) at our institution. Records of all patients who received standard myeloablative allogeneic SCT for MM were retrospectively reviewed. Overall survival (OS), progression-free survival (PFS), and event-free survival (EFS) were calculated using the Kaplan-Meier method. In total 37 transplants had been performed. Median follow up post-SCT was 108 months (range: 33-148). The majority of patients suffered advanced stage disease and/or had received multiple prior therapies prior to SCT. Transplant-related mortality (TRM) at 100 days was 32%. Grades 2-4 acute graft-vs.-host disease (GVHD) occurred in 18 patients (49%), and extensive stage chronic GVHD in seven (28%) of 25 patients surviving greater than day 100. Median OS, PFS, and EFS were 28 months, 66 months and 13 months, respectively, with 5 year OS, PFS, and EFS 40%, 54% and 24%. Our results suggest that allogeneic SCT, even when performed in advanced stage, heavily pretreated MM, still results in long-term EFS in a significant minority of patients. Efforts should continue on alternative allogeneic SCT approaches to reduce the high early TRM rate associated with myeloablative conditioning.
机译：总结我们的目的是回顾我们机构对多发性骨髓瘤（MM）进行的清髓同种异体干细胞移植（SCT）的长期结果。回顾性地回顾了所有接受MM的标准清髓异基因SCT的患者的记录。使用Kaplan-Meier方法计算总生存期（OS），无进展生存期（PFS）和无事件生存期（EFS）。总共进行了37次移植。 SCT后的中位随访时间为108个月（范围：33-148）。大多数患者患有晚期疾病和/或在SCT之前接受过多种先前的治疗。 100天时的移植相关死亡率（TRM）为32％。生存于100天以上的25名患者中，有18名患者（49％）发生2-4级急性移植物抗宿主病（GVHD），广泛阶段性慢性GVHD发生在25名患者中。其中7名（28％） EFS分别为28个月，66个月和13个月，其中5年OS，PFS和EFS分别为40％，54％和24％。我们的结果表明，即使在晚期阶段进行了高度预处理的MM，同种异体SCT仍会在相当少数患者中导致长期EFS。应继续努力进行其他同种异体SCT方法，以减少与清髓性调理相关的高早期TRM率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号